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Twelve analogues of diclofenac (1), a nonsteroidal antiinflammatory drug and known inhibitor
of transthyretin (TTR) amyloid formation, were prepared and evaluated as TTR amyloid
formation inhibitors. High activity was exhibited by five of the compounds. Structure-activity
relationships reveal that a carboxylic acid is required for activity, but changes in its position
as well as the positions of other substituents are tolerated. High-resolution X-ray crystal
structures of four of the active compounds bound to TTR were obtained. These demonstrate
the significant flexibility with which TTR can accommodate ligands within its two binding
sites.
Introduction
Transthyretin (TTR) is a tetrameric protein made up
of four identical â-sheet sandwich subunits, each com-
posed of 127 amino acids.1,2 TTR is present at a
concentration of approximately 0.2 mg/mL (3.6 íM) in
human plasma,3,4 where it is a secondary carrier of the
thyroid hormone thyroxine (thyroid binding globulin
being the primary carrier)3,5 and the sole transporter
of the retinol binding protein-vitamin A complex.6 In
cerebrospinal fluid it is present at approximately 10-
fold lower concentration4 and is the primary carrier of
thyroxine.7 Under acidic conditions, like those found
in cellular organelles such as the lysosome, TTR dis-
sociates to an alternatively folded, monomeric inter-
mediate that self-assembles into amyloid fibrils.8-12 The
deposition of wild type TTR amyloid has been implicated
to cause the disease senile systemic amyloidosis (SSA),
whereas the deposition mutant TTR amyloid has been
implicated to cause the diseases familial amyloid cardio-
myopathy (FAC) and familial amyloid polyneuropathy
(FAP); over 80 variants of TTR have been associated
with FAC and FAP.13,14 SSA involves the deposition of
amyloid in the heart, with symptoms typically appear-
ing around ages 70 to 80.15 FAP and FAC involve the
deposition of amyloid in either the peripheral nerves
(FAP) or the heart (FAC), with symptoms typically
appearing much earlier than in SSA.14,16 The most
prevalent form of FAP is associated with the V30M
variant of TTR, with disease onset occurring in the mid-
30s to early 40s.13,14 The most severe form of FAP is
associated with the L55P variant of TTR, with disease
onset occurring in the second decade of life.17 A com-
parison of the X-ray crystal structures of wild type,
V30M, and L55P TTR does not reveal any differences
that can explain the amyloidogenicities of the latter two
variants,18 nor is the function of the variants noticeably
compromised. All evidence suggests that these are
gain of toxic function diseases associated with the
process of amyloid fibril formation. Consistent with this,
L55P TTR is markedly less stable to acid-induced
tetramer dissociation and amyloid formation than V30M
TTR, which is in turn less stable than wild type
TTR.11,19-21 Thus, for these three variants, the ages of
onset of TTR amyloid diseases correlate directly with
the acid stabilities of the TTR tetramers involved.
The only treatment for FAP that has proven success-
ful is liver transplantation, a form of gene therapy in
which the mutant gene is replaced with the wild type
in the organ that secretes the protein into the plasma.22
While this demonstrates that TTR amyloid diseases can
be treated by removing the amyloidogenic protein, it is
severely limited by the availability of livers for trans-
plantation and the requirement for lifelong immune
suppression. A therapy in which a small molecule drug
inhibits TTR amyloid formation would be preferable.
Evidence that such an approach might be feasible comes
from a simple observation: amyloid formation by TTR
is very rare in tissues bathed by the cerebrospinal fluid23
where TTR is the primary carrier for thyroxine.7 This
is even true in heterozygous FAP patients. Experiments
have shown that the binding of thyroxine by TTR
stabilizes the tetrameric state against acid induced
dissociation, thus preventing amyloid formation in
vitro.24
Because of its hormone activity, thyroxine cannot be
used to inhibit TTR fibril formation in vivo. However,
focused screening and rational design efforts have
resulted in the identification of several structurally
diverse small molecules that, like thyroxine, bind to and
stabilize TTR under fibrillogenic conditions.25-30 The
active structural classes include biaryls,26 flavones,26
phenoxazines,29 and diarylamines.26-28 In particular,
the diarylamine diclofenac (1; also known as Voltaren),
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whose structure is shown below, is a promising starting
point for the preparation of a series of analogues that
could be used for the treatment of TTR amyloidosis
because (1) the parent compound is among the most
active fibril formation inhibitors found to date;27,30 (2)
the diarylamine scaffold can be easily prepared with a
wide variety of substituents; and (3) the parent com-
pound has been approved by the FDA as a nonsteroidal
antiinflammatory drug (NSAID),31 indicating that its
analogues are likely to have suitable pharmacological
properties.
Here we describe the design, preparation, fibril
inhibition activity, and TTR cocrystal structures of a
number of diclofenac (1) analogues. The information
gained from these studies is used to develop an under-
standing of the structure-activity relationships that
govern the efficacy of these compounds as inhibitors of
TTR fibril formation.
Binding and Activity of Diclofenac (1)
The TTR homotetramer has 222 symmetry (that is,
three perpendicular C2 symmetry axes), with two funnel
shaped, C2-interconvertable binding sites located at the
dimer-dimer interface.32 Each binding site can be
divided into an inner and an outer cavity, which are
further defined by three symmetry related pairs of
binding pockets. These pockets historically have been
referred to as the halogen binding pockets (HBP)
because they accommodate the iodines of thyroxine.32,33
HBP1 and 1′ are in the outer cavity, HBP 2 and 2′ are
at the interface between the inner and outer cavities,
and HBP 3 and 3′ are in the inner cavity. The cocrystal
structures of a diverse set of small molecules bound to
TTR have been solved and reported.25,29,30,33-37 Many
of these, like diclofenac (1), consist of two aromatic rings
separated by a spacer, with one of the rings bearing a
carboxylate.25,29,30 Such compounds usually bind to TTR
in what is referred to as the “forward mode”, in which
the carboxylate bearing ring occupies the outer binding
cavity. The carboxylate is placed at the periphery of the
cavity, allowing it to make electrostatic interactions
with the -NH3+ groups of Lys 15 and 15′. This is
exemplified by the binding of flufenamic acid, as shown
in Figure 1 (both symmetry related binding modes are
shown, one in green and the other in yellow).25
In striking contrast, diclofenac (1) binds in what is
referred to as the “reverse mode” (Figure 2).30 In the
binding mode shown in yellow, the 2-ethanoic acid
substituted ring of diclofenac (1) occupies the inner
binding cavity where the carboxylic acid forms a hydro-
gen bond with the ç-OH of Thr 119. Across the binding
site, a 120° rotation of the Thr 119′ side chain allows
the hydrophobic portion of the 2-ethanoic acid substi-
tuted ring to fill HBP 3′. The 2,6-dichloro substituted
ring occupies the outer binding cavity where the C3, C4,
and C5 portion of the ring fill HBP 1, interacting with
the side chains of Leu 17, Ala 108, Val 121, and the
ç-methyl group of Thr 119. The chlorine substituents
fill HBP 2 and 2′ at the interface between the inner and
outer binding cavities.
Figure 1. Flufenamic acid bound to TTR in the forward
binding mode, with its carboxylic acid interacting with the
-NH3+ of Lys 15. The two symmetry related binding modes
are shown in green and yellow. Unprimed and primed residue
numbers or HBPs refer to residues or HBPs in different but
symmetry related monomers in the TTR tetramer. The surface
of the binding site is shown in blue (view from interior) and
gray (view from exterior).
Figure 2. Diclofenac (1) bound to TTR in the reverse mode,
with its carboxylic acid interacting with the ç-OH of Thr 119.
As above, the two symmetry related binding modes are shown
in green and yellow, and the binding site’s surface is shown
in blue (view from interior) and gray (view from exterior).
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While diclofenac (1) (and some of its analogues
studied in this work; see below) is the only TTR fibril
formation inhibitor studied to date that has been shown
to bind in the reverse mode,25,29,30 it still exhibits binding
affinity and fibril inhibition activity comparable to the
most active inhibitors that bind in the forward mode.
Diclofenac’s (1) binding to wild type, V30M, and L55P
TTR was characterized by isothermal titration calorim-
etry, and the dissociation constants are listed in Table
1. The first dissociation constants are 15-20-fold lower
than the second dissociation constants in every case,
indicating that diclofenac (1) binds with negative coop-
erativity (which is typical for the binding of small
molecules to TTR). Diclofenac’s (1) dissociation con-
stants to the various TTR variants are comparable to
those of flufenamic acid, the benchmark for TTR fibril
formation inhibitors.25
The activity of diclofenac (1) as a fibril formation
inhibitor was measured previously against wild type
TTR.27,30 Fibril formation after 72 h of incubation at pH
4.4 (enough time to reach the plateau phase for TTR
amyloid fibril formation) was reduced by 65% at a
diclofenac (1) concentration sufficient to load one of the
two TTR binding sites. At a concentration sufficient to
load both of the binding sites, fibril formation was
reduced by 83% (compare to reductions of 74% and 97%
for flufenamic acid at the same concentrations).25,29
Design of Analogues
To probe how the display of functional groups on
diclofenac’s (1) diarylamine scaffold relates to its fibril
inhibition activity and unique binding mode, the ana-
logues shown in Figure 3 were prepared and assayed.
In several cases, their cocrystal structures with TTR
were determined. The importance of diclofenac’s (1)
2-ethanoic acid functional group as a hydrogen bond
acceptor for the hydroxyl of Thr 119 was examined using
analogues 2-5, in which this substituent has been
modified. In 2 and 3 the acid has been replaced by a
methyl ester and an alcohol respectively, functional
groups that have only modest potency as hydrogen bond
acceptors.38 The primary amide in 4 is a much stronger
hydrogen bond acceptor than an ester or an alcohol,38
but it is weaker than a charged carboxylate. The
2-methanoic acid in 5 retains the carboxylic acid func-
tionality, but eliminates the aliphatic spacer between
it and the aryl ring. The importance of having a polar
functional group to interact with the residues that line
the inner binding cavity was evaluated using 6-9. In
these diclofenac (1) analogues, the 2-ethanoic acid
functionality was replaced by chloroethyl, ethyl, isopro-
pyl, and propyl groups, respectively. The importance of
the 2,6-dichloro substitution pattern in 1 and 5 was
examined using 10 and 11, in which the chlorines were
moved from the 2 and 6 positions to the 3 and 5
positions. The effect of placing a carboxylate in the 4
position of the 2,6-dichloro substituted ring while re-
taining the 2-ethanoic acid group on the other was
evaluated using 12. The 4-carboxylate was envisioned
to form an electrostatic interaction with the Lys 15 and
15′ -NH3+ groups if it bound in the same orientation
as diclofenac (1). Finally, analogue 13 was prepared to
determine the effect of having a negatively charged
substituent only on the dichloro-substituted ring. The
4-nitro group on the other ring was required for ease of
synthesis (see below).
Results
Synthesis of Diclofenac (1) Analogues. A number
of the compounds shown in Figure 3 have been prepared
and studied previously (2,39 3,40,41 4,39 5,42-46 10,47 and
1142-45,48) to evaluate their activities as antiinflamma-
tories, analgesics, etc. Synthetic details are reported
here only when our procedures differ significantly from
those already reported.
Analogues 2-4 in which the 2-ethanoic acid substitu-
ent is modified were prepared starting from the com-
mercially available sodium salt of diclofenac (1), as
shown in Scheme 1. The free acid was obtained by
dissolution of the sodium salt in water followed by
acidification and extraction. Treatment with trimethyl-
Table 1. First (Kd1) and Second (Kd2) Dissociation Constants of
the Binding of Diclofenac (1) to Wild Type, V30M, and L55P
TTR Determined by Isothermal Titration Calorimetry
protein Kd1 (nM) Kd2 (nM)
wild type 60 ( 30 1200 ( 860
V30M 160 ( 70 3900 ( 730
L55P 380 ( 190 6180 ( 1300
Figure 3. Analogues of diclofenac (1) prepared for this study.
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silyldiazomethane yielded the methyl ester 2, which was
in turn converted to alcohol 3 by reduction with LiAlH4.
The primary amide 4 was obtained directly from the
sodium salt of diclofenac (1) by activation with PyBOP
followed by addition of NH4OH. The 2-methanoic acid
analogue, 5, is a known compound and was prepared
as described by Chalmers et al.42
The members of the remaining three groups of
analogues displayed in Figure 3 were prepared by
coupling anilines with aryl halides or triflates (except
for alkyl chloride 6, which was prepared by CCl4-PPh3
reaction with alcohol 3;49 see Scheme 1). For 7, 8, 9, 11,
and 13, the necessary coupling was accomplished using
the palladium coupling chemistry developed by Buch-
wald50 and Hartwig.51 The anilines listed in Scheme 2a
were coupled to the necessary aryl halides or triflates
in refluxing toluene using the Pd2(dba)3/racemic BINAP
catalyst and Cs2CO3 as a base in 47-85% yield. The
esters of 11 and 13 were hydrolyzed using LiOH in THF:
MeOH:H2O (3:1:1).
The Pd-mediated coupling reaction failed when used
for the preparation of 10 and 12, yielding either unre-
acted starting materials (10) or a complex mixture (12).
Compound 10 had been prepared previously using the
copper-mediated Ullman reaction.47 This procedure
successfully yielded 10 and was adapted for the syn-
thesis of 12 as shown in Scheme 2b. The anilines listed
in Scheme 2b were coupled to N,N-dimethyl-2-iodo-
acetamide in refluxing toluene in the presence of CuI,
activated Cu, and anhydrous K2CO3, yielding 10 and
12 as their dimethylamide protected derivatives. These
were hydrolyzed to the corresponding acids using KOH
in refluxing ethanol. N,N-Dimethyl-2-iodoacetamide
was prepared by treating 2-iodophenylacetic acid with
HBTU in the presence of dimethylamine hydrochloride
and triethylamine.
Inhibitory Activities of 2-13. The activities of
diclofenac (1) analogues 2-13 as inhibitors of wild type,
V30M, and L55P TTR fibril formation under conditions
that simulate those found in the lysosome were deter-
mined using a stagnant fibril formation assay.9,24 In this
assay, the compound under evaluation is first incubated
for 30 min with TTR at neutral pH (37 °C). The pH is
then lowered to give the maximal rate of fibril formation
for a given variant (4.2 for wild type or 5.0 for V30M
and L55P), and the samples are incubated for 72 h at
37 °C. The extent of fibril formation in the sample of
interest is determined by comparing its turbidity at 400
nm to that of a sample of TTR in the absence of any
test compound. The ratio of the turbidities of the
samples with and without inhibitor multiplied by 100%
gives the percent fibril formation, or % FF, that char-
acterizes the test compound’s activity. A low % FF (e.g.,
4% FF) corresponds to high inhibitory activity (96%
inhibition). The efficacies of compounds 2-13 in terms
of % FF are summarized in Table 2. A limiting amount
of test compound per equivalent of TTR tetramer was
used, such that only one of TTR’s two binding sites could
be occupied. This was done so that the inhibitory
activities would be measured under the most stringent
conditions.
With one equivalent of inhibitor bound per equivalent
of TTR tetramer, a % FF of 40% or less indicates high
Scheme 1. Synthesis of 2, 3, 4, and 6 from Diclofenac Scheme 2. (a) Synthesis of 7-9, 11, and 13 by the
Palladium Catalyzed Coupling of Anilines with Aryl
Halides or Triflates and (b) Synthesis of 10 and 12 by
the Copper-Mediated Ullman Reaction
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activity, a % FF between 40% and 70% indicates modest
activity, and a % FF greater than 70% indicates weak
activity.24-29
To ensure that these compounds inhibit TTR fibril
formation by tetramer stabilization, the quaternary
structures of wild type, V30M, and L55P TTR were
evaluated by analytical ultracentrifugation in the pres-
ence of 10, 12, and 13 (3 equiv) at the pH maximum for
fibril formation. The tetramer was the dominant species
in all cases, and in only one case (L55P TTR with 10)
did larger aggregates make up more than 10% of the
total amount of protein detected (see Table 3).
Crystal Structures of Inhibitors Bound to TTR.
Cocrystals of diclofenac (1) analogues 10, 11, 12, and
13 bound to wild type TTR were obtained by soaking
TTR crystals with a 10-fold excess of inhibitor for four
weeks.25,30 High-resolution X-ray structures, depicted in
Figures 4-7, were then solved for each of these. Two
symmetry related binding modes were observed in all
cases because of the C2 axis of symmetry running
through the center of the binding site. The inhibitors
all bind in conformations that resemble their minimum
energy conformations, as determined by molecular
mechanics minimizations using the program Insight II
(Molecular Simulations Inc.). The unique features of
each structure are described below. Note that primed
and unprimed residue numbers refer to residues that
are interconverted by rotation about the C2 axis of
symmetry mentioned above.
(a) Compound 10 Bound to TTR. Compound 10
differs from diclofenac (1) only in that its chlorine
substituents are in the 3 and 5 positions rather than
the 2 and 6 positions. This similarity in structure leads
to a similarity in the ways that 10 and diclofenac (1)
bind: both bind in the reverse mode, and although 10
penetrates approximately 1 Å deeper into the binding
site, the interactions between it and TTR are similar to
those observed for diclofenac (1). In the binding mode
shown in yellow in Figure 4, the hydroxyl groups of Ser
117 and Thr 119 are rotated toward 10, making HBP 3
relatively hydrophilic. A hydrogen bond forms between
the carboxyl of 10 and the ç-OH of Thr 119. The ring
fills the more hydrophobic HBP 3′ on the other side of
the cavity. The 3,5-dichloro substituted ring occupies
the outer cavity. The 3,5 substitution pattern allows the
two chlorine atoms to fill HBP 1 and 1′, rather than 2
and 2′ as in diclofenac (1). The aromatic ring interacts
with the side chains of Leu 17 and Ala 108, and the
aliphatic portion of the Lys 15 side chain. In particular,
the interactions between the Lys ç- and ä-carbons force
the -NH3+ into a position to form a salt bridge with
the ä-COO- of Glu 54, an interaction that is not
observed with diclofenac (1).
(b) Compound 11 Bound to TTR. Compound 11
differs from diclofenac (1) both in the 3,5-dichloro
substitution pattern on one ring and in the presence of
a 2-methanoic instead of a 2-ethanoic acid substituent
on the other. These modifications do not, however, cause
11 to abandon the reverse binding mode. Figure 5
demonstrates that the carboxylic acid bearing aromatic
ring still occupies the inner cavity, where it is able to
hydrogen bond to the hydroxyls of both Ser 117 and Thr
Table 2. Percent Fibril Formation (% FF) Data for Compounds
2-13 against Wild Type, V30M, and L55P TTRa
a The error in these assays is (5%.
Table 3. Quaternary Structure of the Soluble Protein after
Incubation of 3.6 íM Wild Type, V30M, and L55P TTR with
10.8 íM of 10, 12, and 13 under Fibril Formation Conditions
for 72 h
compd protein
%
tetramer
%
monomer
%
aggregate
MW
(kDa)
10 wild type >95 55
V30M >95 55
L55P 76 24 55
12 wild type 95 5 50
V30M >95 53
L55P >95 49
13 wild type 93 7 53-56
V30M 90 10 47
L55P >95 49-55
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119 in HBP 3. The remainder of the aromatic ring again
resides in HBP 3′ on the other side of the cavity. The
3,5-dichloro substituted ring is less twisted relative to
the carboxylic acid bearing ring in 11 than it is in 10 or
diclofenac (1). This only leads to slight differences in
the contacts it makes in the outer cavity. The chlorine
atoms still fill HBP 1 and 1′, and the ring still interacts
with Lys 15, Leu 17, and Ala 108. Here, though, the
interaction with Lys 15 is a van der Waals interaction
through the -CH2 and the salt bridge between Lys 15
and Glu 54 does not form.
(c) Compound 12 Bound to TTR. The terms
“forward” and “reverse” are ambiguous when describing
the binding of 12 to TTR because both of its rings have
carboxylate substituents. Its binding can be said to be
analogous to that of diclofenac (1) in that its 2-ethanoic
acid bearing ring occupies the inner binding cavity, but
there are several differences in the details that char-
acterize the binding of 12 and diclofenac (1). The binding
mode shown in yellow in Figure 6 shows that 12 does
not reside as deep in the binding site as diclofenac (1).
The hydrogen bond between the COO- of 12 and the
ç-OH of Thr 119 is relatively weak (3.4 Å O-O dis-
tance), and the side chain of Ser 117 is rotated so that
its hydroxyl is pointed away from the cavity. It forms a
Figure 4. Compound 10 bound to TTR in two symmetry
related binding modes shown in yellow and green. The surface
of the binding site is shown in blue (view from interior) and
gray (view from exterior).
Figure 5. As Figure 4, but with 11 bound to TTR.
Figure 6. As Figure 4, but with 12 bound to TTR.
Figure 7. As Figure 4, but with 13 bound to TTR.
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van der Waals interaction with 12, between its â-CH2
and the CH2 of the ethanoic acid. The strongest hydro-
gen bonds between 12 and TTR occur between the
COO- of 12 and the main chain NHs of residues Ala
108, Ala 109, and Leu 110. The 2,6-dichloro-4-carboxylic
acid substituted ring resides in the outer binding cavity.
As with diclofenac (1), the chlorine substituents fill
HBP 2 and 2′, which allows the 4-COO- to make an
additional electrostatic interaction with the -NH3+ of
Lys 15, as intended.
(d) Compound 13 Bound to TTR. Although 13
differs from 12 only in that it has a 4-NO2 aryl ring
rather than a 2-ethanoic acid aryl ring, it binds to TTR
in an orientation opposite to that of 12. In the binding
mode shown in yellow in Figure 7, 13 binds with its
2,6-dichloro-4-carboxylic acid substituted ring very deep
in the inner cavity. This is accommodated by a rotation
of the Thr 119 side chain, which allows the 4-COO- to
be fairly close to the bottom of the cavity where it can
hydrogen bond to the side chain hydroxyl of Ser 117.
The chlorine substituents fill HBP 2 and 2′, just as in
diclofenac (1) and 12, except that they are projected into
the pockets from the opposite direction; that is, from
the inner cavity rather than the outer cavity. The 4-NO2
substituted ring fills the outer binding cavity. The ring
itself interacts mainly with the residues of HBP 1, while
the nitro group forms a hydrogen bond with the -NH3+
of Lys 15, and a water mediated hydrogen bond with
the -NH3+ of Lys 15′. Note that compound 13 can also
be considered to bind in the reverse mode (although this
nomenclature clearly has its limitations), as its COO-
bearing ring binds in the inner cavity.
Discussion
Structure-Activity Relationships. The relation-
ships between the structures of compounds 2-13 and
their fibril inhibition activities against wild type TTR
are dominated by the importance of having a negatively
charged substituent on one of the rings. This is evident
not only from the poor fibril inhibition activities of 6-9,
in which the carboxylic acid is replaced by purely
hydrophobic groups, but also from the poor fibril inhibi-
tion activities of 2-4, in which the carboxylic acid is
replaced by uncharged polar groups. Apparently, it is
not sufficient to have a hydrogen bond acceptor in the
molecule; compound 4, for example, has an excellent
hydrogen bond acceptor in its primary amide, yet it is
still only weakly active. A negatively charged substitu-
ent is an absolute requirement for high activity in this
series of compounds.
While the presence or absence of negative charge has
a strong influence on activity, the exact location of the
charge does not. High activity is maintained with the
charged group attached to the ring via a methylene
spacer (as in diclofenac (1) or 10), or with it directly
attached (as in 5 or 11). Furthermore, having the charge
on a separate ring from the chlorines is also not required
for activity, as is apparent from 13 (although it is
important for the binding orientation; see below).
The position of the chlorine substituents was expected
to be important for fibril inhibition activity since it
affects the degree of twist between the two rings of the
diarylamine, and degree of twist has been shown to be
important to other activities of diclofenac (1) analogues47
and N-phenyl anthranilic acids.43 However, comparing
the activities of diclofenac (1) and 5, in which the
chlorines are in the 2 and 6 positions, to those of 10
and 11, in which they are in the 3 and 5 positions,
reveals that this is not the case. It should be noted that
N-phenyl anthranilic acid, the analogue of 5 and 11 in
which there are no chlorine substituents, has been found
to have moderate fibril inhibition activity (% FF ) 51%
at 1 equiv TTR tetramer).27 Thus, the presence of the
chlorines affects activity, even though variation in their
positions is tolerated.
Of the three TTR variants studied, the fibril inhibition
activities for 2-13 were generally lowest against L55P
TTR (consistent with earlier observations24,25,29), and
about the same against V30M and wild type TTR. The
structure-activity relationships for 2-13 are the same
for V30M TTR as they are for wild type TTR, and mostly
the same for L55P TTR: a charged functional group is
required for high activity in all cases, and the distance
of the charge from the ring and the pattern of chlorine
substitution can be manipulated without abridging
activity. The only notable difference among the different
TTR variants is that 10, 11, and 12 have somewhat
higher activities than diclofenac (1) against L55P TTR
fibril formation, whereas they have about the same
activities as diclofenac (1) against V30M and wild type
TTR. In fact, 10, 11, and 12 are among the most active
inhibitors against fibril formation by L55P that have
been discovered to date.24,25,29 This result is difficult to
rationalize because residue 55 is not directly involved
in ligand binding, but whatever subtle changes cause
the increased amyloidogenicity of L55P TTR may be
responsible for the differences observed here.
The Reverse Binding Mode. X-ray crystal struc-
tures of four of the compounds evaluated herein bound
to wild type TTR were solved. Three of these (10, 11,
and 13) are, like diclofenac (1), bound in the reverse
mode with their carboxylic acid substituted rings oc-
cupying the inner cavity. The remaining compound
(12) cannot be said to bind in the reverse mode be-
cause both of its rings bear carboxylic acids, yet its
mode of binding is clearly analogous to diclofenac’s
(1) in that its 2-ethanoic acid substituted aryl ring
occupies the inner binding cavity. This shows the
adaptability of the reverse binding mode in the face
of significant structural variation in the ligands. The
structures shown in Figures 4-7 provide two reasons
for why this binding mode should be so robust. First,
there are functional groups capable of making polar
interactions all throughout the inner cavity. Ligands
that bind deep in the binding site, like 13, can hydrogen
bond to the side chain hydroxyl of Ser 117 at the bottom
of the cavity; ligands that bind shallow in the binding
site, like 12, can hydrogen bond to the main chain at
residues 108-110; and ligands that bind between these
two extremes, like 10 and diclofenac (1), can hydrogen
bond to the side chain hydroxyl of Thr 119. Second, the
three pairs of halogen binding pockets allow ligands to
optimize their polar interactions without compromising
their van der Waals interactions. This can be demon-
strated by comparing the binding of diclofenac (1) to
that of 10. Moving the chlorines from the 2 and 6
positions to the 3 and 5 positions causes them to project
off the diarylamine scaffold at very different angles in
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diclofenac (1) and 10, respectively. This is easily accom-
modated in the binding site by placing the chlorines
in HBP1 and 1′ for 10 instead of HBP2 and 2′ as in
diclofenac (1). The chlorine atoms are satisfied while
simultaneously allowing the 2-ethanoic acid on the other
ring to maintain its interaction with the Thr 119
hydroxyl.
Perhaps the best illustration of the powerful interac-
tions made in the reverse binding mode comes from
comparing the cocrystal structures of diclofenac (1), 12,
and 13. Adding a 4-carboxylate to the 2,6-dicloro
substituted ring in diclofenac (1) results in 12. The effect
of this change on the binding is mild. The extra
carboxylate is able to satisfy itself by interacting with
the -NH3+ of Lys 15 while the binding orientation
remains constant. The 2-ethanoic acid substituted ring
still resides in the inner cavity, and the 2,6-dichloro
substituted ring still resides in the outer cavity. Elimi-
nating the 2-ethanoic acid in 12 and adding a 4-nitro
group results in 13. The effect of this change on the
binding is drastic. Compound 13 has only one charged
functional group, and it is on the same ring as the
chlorine substituents. To maintain the reverse binding
mode, the 2,6-dichloro substituted ring occupies the
inner cavity, a condition unique to 13. The advantages
of keeping the negatively charged functional group in
the inner cavity here seem to outweigh any disadvan-
tages that might have arisen from taking the chlorine
substituents out of the outer cavity.
The cocrystal structures of wild type TTR with 10-
13 show the versatility and strength of the interactions
in the reverse binding mode. There is also evidence from
previous studies of similar versatility and strength in
the forward binding mode.25,30 Unfortunately, the sys-
tematic variation of the diclofenac (1) structure in this
study has yielded only compounds that bind in the
reverse mode, leaving no basis for a supposition as to
which structural features of diclofenac (1) impart its
binding preferences to it. The reasons that flufenamic
acid, o-trifluoromethylphenyl anthranilic acid, and flur-
biprofen bind in the forward mode while diclofenac (1)
and its analogues bind in the reverse mode remain
opaque. However, the ability of TTR to bind ligands in
either of two highly adaptable modes provides an
explanation for another facet of its binding to small
molecules. It has been observed that TTR, like albumin,
is quite promiscuous in its binding to small molecules.
The range of structures that are competent as amyloid
fibril formation inhibitors has been alluded to above; it
has also been found in unrelated studies that TTR binds
to aurones,37 bipyridines,35 retinoic acid (even without
the intermediacy of retinol binding protein),52 and
various organic halogen substances (OHS).34,53-56 In
fact, it has been suggested that TTR transports poly-
chlorinated biphenyls in vivo.53 The exceptional plastic-
ity in the requirements for small molecule binding to
TTR probably stems from the existence of two different
modes for ligand binding, each of which is able to
tolerate significant structural variation.
Outlook for Diclofenac (1) Analogues as Thera-
peutics for TTR Amyloidosis. Six of the compounds
in this study (diclofenac (1), 5, and 10-13) are highly
effective as inhibitors of amyloid formation by TTR.
However, in order for any of these to serve as thera-
peutics for TTR amyloidosis, they must meet two
requirements in addition to high activity. First, they
must partition into TTR in the presence of all of the
other plasma proteins; if they were taken up by other
proteins in the blood, then they could not possibly serve
to stabilize TTR against amyloid formation during
protein turnover. Second, they must have good phar-
macological properties, that is, satisfactory bioavailabil-
ity, half-lives, etc. Data relevant to the first matter have
recently been reported. It was found that while di-
clofenac (1) itself did not partition effectively into TTR
in human plasma, 10 and especially 11 did.57 When 10
(10.8 íM) was added to human plasma, 0.68 equiv of
10 (out of a maximum of 2 equiv) were bound to TTR.
Under the same conditions, more than twice as much
(1.38 equiv) of 11 was bound to TTR.57 It seems that
the exact positions of the chlorine and carboxylic acid
substituents are very important to the partitioning into
TTR, even though these factors do not strongly affect
activity. The second matter will be addressed by testing
promising compounds from this study (especially 10 and
11) in mouse models for TTR amyloidosis.58 The results
of these studies will be reported in due course.
Experimental Section
General Aspects. All glassware was flame dried and cooled
under positive argon pressure. All reactions were performed
under argon except for the hydrolysis reactions. Reagents and
solvents were purchased from Aldrich, Lancaster, Acros,
Advanced ChemTech, or Pfaltz-Bauer. THF was dried by
passage over Al2O3, while isopropyl alcohol was distilled from
CaO. Other solvents and reagents were used as obtained from
the manufacturer. Reactions were monitored by thin-layer
chromatography (TLC) on silica gel 60F254-coated aluminum
TLC plates purchased from EM Science. Unless stated other-
wise, product purification was performed by flash chromtog-
raphy using silica gel (230-400 mesh) purchased from EM
Science. The purities of new compounds that were essential
to the conclusions drawn in the text (6, 7, 8, 12, and 13) were
determined by HPLC. Normal phase HPLC was performed
with a Waters 600 controller, a Waters 996 photodiode array
detector, and a Waters NovaPak Silica column. The solvent
system was hexanes and ethyl acetate, and gradients were run
from 100:0 hexanes:ethyl acetate to 0:100 hexanes:ethyl
acetate over 30 min. Reverse phase HPLC was performed with
a Waters 600 detector, a Waters 2487 dual wavelength
detector, and a Vydac Protein and Peptide C18 column. The
solvent system was 95:5 water:acetonitrile (A) and 5:95 water:
acetonitrile (B; A and B both have 0.1% trifluoroacetic acid),
and gradients were run from 100:0 A:B to 0:100 A:B over 40
min, then held at 100% B for 10 min. All HPLC traces are
available in the Supporting Information. 1H NMRs were
obtained on a Bruker NMR spectrometer at 600 MHz, and 13C
NMRs were acquired at 150 MHz unless otherwise noted.
Chemical shifts are reported in ppm relative to CDCl3 (7.26
ppm for 1H NMR and 77 ppm for 13C NMR) or CD3OD (3.31
ppm for 1H NMR and 49.15 ppm for 13C NMR). Mass spectra
were obtained at The Scripps Research Institute Center for
Mass Spectrometry. The fast atom bombardment (FAB) and
MALDI-TOF mass spectra were obtained using NBA/NaI
matrix.
Methyl 2-[(2,6-Dichlorophenyl)amino]benzene Acetate
(2). To a flame dried round-bottom flask equipped with a stir
bar and a rubber septum was added diclofenac (1) (2.96 g, 10
mmol) which was dissolved in methanol (10 mL) and benzene
(30 mL). The reaction mixture was vented through a bubbler
to allow an outlet for the nitrogen produced during the course
of the reaction. Trimethylsilyldiazomethane (TMSCHN2, 2 M
solution in hexanes, 7 mL, 14 mmols) was added dropwise to
the solution. Upon completion of the addition of TMSCHN2, a
yellow color persisted, and the reaction mixture was allowed
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to stir under argon for an additional hour. At the end of this
period, the solvent was evaporated yielding a syrup that
solidified when dried under vacuum. The crude product thus
obtained was purified by flash chromatography using a gradi-
ent of EtOAc in hexane (5-40%) to obtain 2 (2.97 g, 96%). 1H
NMR (CDCl3): ä 7.98 (dd, J ) 7.9, 1.8 Hz, 1H), 7.40 (ddd, J )
7.9, 7.7, 1.3 Hz, 1H), 7.32 (d, J ) 7.9 Hz, 1H), 7.11 (d, J ) 1.7
Hz, 1H), 7.00 (dd, J ) 1.7, 1.7 Hz, 1H), 6.85 (ddd, J ) 7.9, 7.4,
0.8 Hz, 1H), 3.73 (s, 2H), 3.66 (s, 3H). 13C NMR (CDCl3): ä
168.70, 145.73, 143.31, 135.50, 134.24, 131.76, 122.49, 118.98,
118.84, 115.12, 113.59, 52.02. HRMS: calculated for C15H13-
Cl2NO2 M+ ) 309.0323, found 309.0319.
2-[(2,6-Dichlorophenyl)amino]benzene-ethan-1-ol (3).
A round-bottom flask equipped with a magnetic stir bar and
a rubber septum was charged with 2 (2.34 g, 7.55 mmol), which
was then dissolved in 15 mL of THF. The 0.5 M homogeneous
solution of 2 in THF was cooled to -22 °C in a dry ice-CCl4
bath, and LiAlH4 (0.344 g, 9.06 mmol) was added in small
portions. The reaction mixture was stirred at -22 °C for 4 h,
after which the dry ice-CCl4 bath was removed, and the
reaction mixture was stirred overnight at 25 °C. The reaction
was quenched with the dropwise addition of KHSO4 (10% in
H2O, 25 mL) and transferred to a separatory funnel. The
product was extracted into the organic layer using EtOAc (3
 50 mL). The organic layer was concentrated on a rotary
evaporator. Purification of the crude product by flash chro-
matography using a gradient of EtOAc and hexanes (5-40%)
yielded the desired product 3 (0.98 g, 46%) as an off-white solid.
1H NMR (CDCl3): ä 7.33 (d, J ) 8.3 Hz, 2H), 7.19 (dd, J )
7.5, 1.3 Hz, 1H), 7.08 (ddd, J ) 7.7, 7.7, 1.3 Hz, 1H), 6.98 (dd,
J ) 8.3, 7.9 Hz, 1H), 6.93 (dd, J ) 6.6, 6.5 Hz, 1H), 6.48 (d, J
) 7.4 Hz, 1H), 4.02 (t, J ) 5.7 Hz, 2H), 3.02 (t, J ) 5.6 Hz,
2H). 13C NMR (CDCl3): ä 142.59, 137.66, 130.62, 129.78,
129.02, 128.86, 128.63, 126.98, 124.03, 121.60, 116.83, 64.22,
34.77. HRMS: calculated for C14H13Cl2NO M+ ) 281.0374,
found 281.0371.
2-[(2,6-Dichlorophenyl)amino] Benzeneacetamide (4).
A round-bottom flask was charged with a stir bar, the sodium
salt of diclofenac (1) (Sigma, 318 mg, 1 mmol), and PyBop
(benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluo-
rophosphate; 520 mg, 1 mmol), and capped with a septum. The
solvent CH2Cl2 (10 mL), DIEA (diisopropylethylamine; 391 íL,
2.25 mmol), and 30% aqueous NH4OH (1.3 mL, 19.4 mmol)
were added sequentially to the reaction mixture via syringe
through the septum. The reaction mixture was allowed to stir
at room temperature for 2 h, then concentrated to dryness on
a rotary evaporator and dissolved in EtOAc (50 mL). The
EtOAc layer was washed with brine (2  20 mL) and dried
with MgSO4. The organic layer was concentrated and subjected
to flash chromatography using 30% EtOAc in hexanes to yield
36 mg (12%) of 4 as a white solid. 1H NMR (CDCl3): ä 7.50 (d,
J ) 7.9 Hz, 2H), 7.32-7.39 (m, 2H), 7.19-7.21 (m, 1H), 7.08-
7.10 (m, 1H), 6.40 (d, J ) 7.9 Hz, 1H), 3.77 (s, 2H). 13C NMR
(100 MHz, CDCl3): ä 173.56, 143.21, 135.42, 130.73, 130.34,
128.97, 127.85, 124.74, 124.21, 123.00, 109.06, 35.66. HRMS:
calculated for C14H10Cl2NO (loss of NH2) M+ ) 278.0134, found
278.0132.
2-[(2,6-Dichlorophenyl)amino]benzoic Acid (5). Pre-
pared as described by Chalmers et al.42 Melting point: 219-
221 °C (lit. 220-222 °C). 1H NMR (DMSO-d6): ä 9.55 (d, J )
7.7 Hz, 1H), 7.62 (d, J ) 7.7 Hz, 2H), 7.32-7.40 (m, 2H), 6.81
(t, J ) 7.3 Hz, 1H), 6.24 (d, J ) 8.1 Hz, 1H). 13C NMR
(CDCl3): ä 170.00, 147.01, 134.77, 134.06, 133.42, 131.49,
129.11, 128.27, 117.44, 112.99, 111.93. HRMS: calculated for
C13H9Cl2NO2Na M+Na+ ) 303.9904, found 303.9903.
1-Chloro-2-[(2,6-dichlorophenyl)amino]benzene-eth-
ane (6). A round-bottom flask was charged with compound 3
(0.56 g, 2.0 mmol), a stir bar, and a rubber septum. Triphenyl-
phosphine (0.58 g, 2.2 mmol) was added, and the reaction flask
was cooled to 0 °C using an ice water bath. Finally, pyridine
(2 mL, 25 mmol) was added slowly followed by CCl4 (1 mL,
10.4 mmol). The resulting solution was allowed to warm
gradually to room temperature. The reaction mixture was
partitioned between water and ethyl acetate (10:30 mL), and
the organic layer was washed with 1 N HCl (10 mL), 10%
NaHCO3 (10 mL), then brine (10 mL). The organic layer was
dried over anhydrous Na2SO4, filtered, and concentrated to
obtain crude product that was purified by flash chromatogra-
phy using a gradient of EtOAc in hexanes (5-40%) to obtain
pure 6 as a yellow-white solid. (0.42 g, 70%). 1H NMR
(CDCl3): ä 7.33 (dd, J ) 7.9, 0.9 Hz, 2H), 7.19 (d, J ) 7.5 Hz,
1H), 7.09 (dd, J ) 8.8, 8.3 Hz, 1H), 6.97 (m, 2H), 6.50 (d, J )
7.9 Hz, 1H), 5.81 (br s, 1H), 3.87 (t, J ) 7.4 Hz, 2H), 3.21 (t,
J ) 7.4 Hz, 2H). 13C NMR (CDCl3): ä 141.69, 137.34, 129.70,
128.81, 127.54, 127.30, 124.39, 122.16, 117.54, 117.52, 43.93,
34.97. HRMS: calculated for C14H12Cl3N M+ ) 299.0035, found
299.0033. Normal phase HPLC retention time: 4.3 min;
reverse phase: 45.2 min, >99% pure.
General Procedure for Pd-Mediated Coupling Reac-
tions to Prepare 7, 8, 9, 11, 13. A round-bottom flask
equipped with a stir bar and a condenser was charged with
an aniline (1 equiv), and Cs2CO3 (1.4 equiv), Pd2(dba)3 (tris-
(dibenzylideneacetone)dipalladium (0); 4.5 mol %), Binap
(racemic 2,2′-bis(diphenylphosphino)-1,1′-binaphthyl; 3 mol %)
and the appropriate halide or triflate (1.2 equiv) were added
in order. Finally, enough toluene to give a 0.5 M solution in
the aniline was added through the septum on the condenser
via syringe, and the reaction mixture was refluxed under argon
for 36 h. The reaction mixture was cooled and filtered through
Celite. The filtrate was concentrated by rotary evaporation and
the crude product purified by flash chromatography using a
gradient of EtOAc in hexanes (5-40%) to obtain pure product
for which the yield ranged from 47% to 85%. The methyl ester
of 11 and the ethyl ester of 13 were hydrolyzed by dissolving
them in THF:MeOH:H2O (3:1:1) to 0.125 M and then adding
4 equiv of LiOH. The reaction mixture was stirred for 4-12 h
and then acidifed to pH 4 using 1 M HCl. The reaction mixture
turned cloudy white at this time, and the product was
extracted into ethyl acetate (3  30 mL). The organic layer
was dried over Na2SO4 (anhydrous) and concentrated on a
rotary evaporator to afford a crude solid that was purified by
recrystallization from 1:1 EtOAc:MeOH with enough added
hexanes to cause precipitation (the final composition was
usually around 1:1:10 EtOAc:MeOH:hexanes) to obtain fluffy
white solids in 60-70% yield.
Characterization for 7, 8, 9, 11, and 13:
2-[(2,6-Dichlorophenyl)amino]benzene-ethane (7). 1H
NMR (CDCl3): ä 7.36 (d, J ) 8.3 Hz, 2H), 7.21 (dd, J ) 7.4,
1.3 Hz, 1H), 7.04 (ddd, J ) 7.7, 7.7, 1.8 Hz, 1H), 7.02 (d, J )
8.3 Hz, 1H), 6.93 (ddd, J ) 7.4, 7.3, 1.3 Hz, 1H), 6.43 (dd, J )
8.1, 0.9 Hz, 1H), 2.75 (q, J ) 7.5 Hz, 2H), 1.34 (t, J ) 7.9 Hz,
3H). 13C NMR (CDCl3): ä 131.75, 130.39, 128.83, 128.57,
126.21, 124.61, 121.43, 115.80, 24.40, 13.48. HRMS: calculated
for C14H13Cl2N M+ ) 265.0425, found 265.0425. Normal phase
HPLC retention time: 3.4 min; reverse phase: 45.1 min, >99%
pure.
2-[(2,6-Dichlorophenyl)amino]benzene-2-methyl-eth-
ane (8). 1H NMR (CDCl3): ä 7.26 (d, J ) 8.0 Hz, 2H), 7.20
(dd, J ) 7.5, 1.5 Hz, 1H), 6.90 (m, 2H), 6.38 (dd, J ) 7.9, 1 Hz,
1H), 5.60 (bs, 1H), 3.21 (m, 1H), 1.275 (d, J ) 6.8 Hz, 6H). 13C
NMR (CDCl3): ä 140.28, 137.66, 136.77, 129.99, 128.85,
125.94, 125.54, 124.26, 121.91, 116.64, 27.71, 22.53. HRMS:
calculated for C15H15Cl2N M+ ) 279.0582, found 279.0573.
Normal phase HPLC retention time: 3.6 min; reverse phase:
46.3 min, >99% pure.
2-[(2,6-Dichlorophenyl)amino]benzene-propane (9).
1H NMR (300 MHz, CDCl3): ä 7.38 (d, J ) 8.1 Hz, 2H),
7.21 (d, J ) 7.2 Hz, 1H), 7.05 (m, 2H), 6.93 (dd, J ) 7.5,
7.2 Hz, 1H), 6.45 (d, J ) 8.1 Hz, 1H), 5.66 (br s, 1H), 2.72
(t, J ) 7.5 Hz, 2H), 1.78 (m, 2H), 1.06 (t, J ) 7.5 Hz, 3H).
13C NMR (75 MHz): ä 141.47, 137.82, 130.91, 130.72, 130.10,
129.26, 126.67, 124.95, 121.75, 116.44, 34.08, 22.82, 14.66.
LRMS: calculated for C15H15Cl2N M+ ) 279/281/283, found
279/281/283.
2-[(3,5-Dichlorophenyl)amino]benzoic Acid (11). 1H
NMR (DMSO-d6): ä 9.56 (bs, 1H), 7.93 (dd, J ) 7.9, 1.3 Hz,
1H), 7.49 (ddd, J ) 7.9, 7.7, 1.7 Hz, 1H), 7.36 (d, J ) 8.3 Hz,
1H), 7.23 (d, J ) 1.7 Hz, 2H), 7.12 (d, J ) 1.7 Hz, 1H), 6.96
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(dd, J ) 7.5, 7.4 Hz, 1H). 13C NMR (DMSO-d6): ä 179.31,
154.29, 144.75, 144.72, 144.17, 141.93, 130.79, 130.02, 127.31,
126.57, 125.88. HRMS: calculated for C13H9Cl2NO2 M+ )
281.0010, found 281.0018.
3,5-Dichloro-4-[(4-nitrophenyl)amino]benzoic Acid (13).
1H-NMR (CDCl3): ä 9.39 (s, 1H), 8.06 (d, J ) 9.2 Hz, 2H), 8.03
(s, 2H), 6.68 (d, J ) 9.2 Hz, 2H); 13C NMR (CDCl3): ä 174.92,
160.54, 148.86, 148.11, 143.22, 139.97, 139.94, 135.95, 123.49.
HRMS: calculated for C13H8Cl2N2O M+ ) 325.9861, found
325.9865. Normal phase HPLC retention time: 20.5 min;
reverse phase: 37.0 min, >99% pure.
General Procedure for Ullman Coupling Reactions To
Prepare 10 and 12. A round-bottom flask equipped with a
magnetic stirbar and a Dean-Stark trap/condenser was
charged with 2-(2-iodo)phenyl-N,N-dimethylacetamide (1 equiv),
the appropriately substituted aniline (2.05 equiv), oven baked
anhydrous K2CO3 (0.8 equiv), freshly activated Cu powder
(0.53 equiv), and CuI (0.053 equiv). Molecular sieves (4 Å) were
placed in a Dean-Stark trap filled with toluene. Additional
toluene (10 mL) was added to the reaction flask, which was
heated at reflux for 100 h. After cooling, the reaction mixture
was filtered through Celite. The filtrate was concentrated,
redissolved in ethyl acetate (30 mL), and washed with water
(10 mL  2). The organic layer was dried (anhydrous Na2SO4),
filtered, and evaporated to a yellowish liquid that was purified
by flash chromatography using a gradient of EtOAc in hexanes
(5-40%) giving the N,N-dimethylamide forms of 10 and 12 in
95% and 97% yields, respectively. These were hydrolyzed by
dissolving the amides at 0.16 M in ethanolic KOH (0.67 M).
This solution was refluxed for 10 h, then cooled to room
temperature and concentrated to a suspension that was
redissolved in 10 mL of water. The aqueous solution was
extracted with ethyl acetate (3  30 mL) to remove any organic
impurities and discarded. The aqueous solution was acidified
using 1 N HCl and extracted with ethyl acetate (3  30 mL).
The combined organics were dried (anhydrous Na2SO4), fil-
tered, and evaporated to dryness on a rotary evaporator. The
product was purified by reverse phase HPLC (in the case of
compound 10; gradient: 90:10 A:B to 15:85 A:B over 30 min
where A was 95:5 water:MeCN + 0.1% TFA and B was 5:95
water:MeCN + 0.1% TFA) or by recrystallization (in the case
of compound 12) from 8.5:1:0.5 hexanes:EtOAc:MeOH.
2-[(3,5-Dichlorophenyl)amino]benzene Acetic Acid (10).
Characterization data for 10 are given here since the 1H NMR
spectrum was measured in a solvent different from that used
previously and because the 13C NMR spectrum for 10 has not
been reported.47 1H NMR (CD3OD, 300 MHz): ä 8.03 (s, 1 H),
7.26-7.36 (m, 2 H), 7.10-7.25 (m, 2 H), 6.77 (dd, J ) 1.5, 1.4
Hz, 1 H), 6.63 (d, J ) 1.8 Hz, 2 H), 3.58 (s, 2 H). 13C NMR
(CD3OD:CDCl3 1:1, 75 MHz): ä 172.82, 149.24, 139.60, 134.77,
132.15, 131.22, 128.43, 125.25, 124.90, 116.75, 112.33, 37.06.
HRMS: calculated for C14H11Cl2NO2 M+ ) 294.00, found
294.00.
2-[(2,6-Dichloro-4-carboxylic acid-phenyl)amino]ben-
zene Acetic Acid (12). 1H NMR (CD3OD): ä 7.92 (s, 2 H),
7.68 (s, 1 H), 7.26 (d, J ) 7.0 Hz, 1 H), 7.12 (dd, J )
7.9, 7.4 Hz, 1 H), 6.97 (dd, J ) 7.4, 7.0 Hz, 1 H), 6.52 (d,
J ) 7.9 Hz, 1 H), 3.72 (s, 2H). 13C NMR (CD3OD): ä
174.37, 165.94, 142.20, 142.11, 131.81, 130.79, 128.31, 128.00,
126.88, 123.42, 123.36, 119.62, 38.70. HRMS: calculated for
C15H11Cl2NO4 M+ ) 339.0065, found 339.0053. Normal phase
HPLC retention time: 19.2 min; reverse phase: 35.3 min, >98%
pure.
2-(2-Iodo)phenyl-N,N-dimethylacetamide. A round-bot-
tom flask was charged with phenyl acetic acid (0.867 g, 3.32
mmol), dimethylammonium hydrochloride (0.245 g, 3 mmol),
and HBTU (1.23 g, 3.3 mmol). Acetonitrile (15 mL) was added,
followed by DIEA (1.62 mL, 9.3 mmol), and the resulting
solution was stirred under argon for 15 h. The reaction mixture
was concentrated to a syrup that was redissolved in EtOAc
(100 mL). The organic layer was washed with 1 N HCl (30
mL) followed by 10% NaHCO3 (30 mL). The organic layer was
dried (anhydrous Na2SO4), filtered, and concentrated. Purifica-
tion of the crude product by flash chromatography using a
gradient of EtOAc in hexanes (5-40%) afforded a colorless oil
that solidified to a white solid under high vacuum (0.82 g,
94%). 1H NMR (CDCl3): ä 7.83 (dd, J ) 8.1, 1.3 Hz, 1H), 7.31
(ddd, J ) 7.5, 7.4, 0.8 Hz, 1H), 7.26 (dd, J ) 7.5, 1.7 Hz, 1H),
6.94 (ddd, J ) 7.5, 7.4, 1.7 Hz, 1H), 3.80 (s, 2H), 3.04 (s, 3H),
3.01 (s, 3H). 13C NMR (CDCl3): ä 170.13, 139.32, 139.29,
138.72, 129.85, 128.48, 101.09, 45.77, 37.66, 35.65.
Stagnant Fibril Formation Assay. The activities of
compounds 2-13 as inhibitors of TTR fibril formation were
ascertained by a stagnant fibril formation assay that has been
described previously.9,24 Briefly, each compound was dried,
then weighed, and dissolved to 7.2 mM in spectroscopic grade
DMSO to yield a primary stock solution. Secondary stock
solutions at 0.72 mM were prepared by a 10-fold dilution of
the primary stocks with DMSO. A typical sample for the
measurement of fibril inhibition was prepared by micropipet-
ting 5 íL of a secondary stock solution into an eppendorf tube
and adding 500 íL of TTR at 0.4 mg/mL in 10 mM sodium
phosphate, 100 mM KCl, and 1 mM EDTA (pH 7.6). The
sample was mixed by vortexing and incubated for 30 min at
37 °C. The pH was lowered to 4.2 (in the case of wild type) or
5 (in the case of L55P and V30M) using 495 íL of acetate buffer
(200 mM acetate, 100 mM KCl, 1 mM ETDA). The resulting 1
mL solution was again vortexed and incubated without further
agitation for 72 h at 37 °C. At the end of this period, the tube
was vortexed to ensure a uniform suspension, and the turbidity
of the suspension at 400 nm was measured (except in the case
of 13, where readings were taken at 600 nm due to the
inhibitor’s red shifted absorbance; note that turbidity is equal
to the optical density at wavelengths where absorbance is
negligible). The ratio of the turbidities of the sample of interest
to that of a sample prepared in the same way but lacking any
inhibitor multiplied by 100% gave the percent fibril formation.
All assays were performed in triplicate, and all compounds
were assayed with wild type, V30M, and L55P TTR (except
for 4 and 5, which were not assayed with L55P). All compounds
were found to be soluble over the course of the experiment,
ensuring that all turbidity was the result of amyloid formation
by TTR.
Isothermal Titration Calorimetry. Dissociation con-
stants for diclofenac (1) binding to wild type, V30M, and L55P
TTR were determined using a Microcal MCS isothermal
titration calorimeter (Microcal Inc., Northhampton, MD). A
solution of diclofenac (1) at 435 íM in 100 mM phosphate
with 100 mM KCl, 1 mM EDTA, pH 7.6, was prepared
(the concentration was determined using 280 ) 10 400 M-1
cm-1, which was determined by measuring the absorbances
of solutions with known amounts of dissolved diclofenac (1)).
This solution was titrated into an ITC cell containing 21.1,
20.1, and 20.0 íM wild type, V30M, and L55P TTR, respec-
tively. The initial injection of 2 íL of diclofenac (1) solution
was followed by 36 injections of 8 íL each (25 °C). Integration
of the thermogram after subtraction of blanks yielded a
binding isotherm that fit best to a model of two interacting
sites exhibiting negative cooperativity. The data were fit
by a nonlinear least squares approach with four adjustable
parameters, namely, K1, ¢H1, K2, and ¢H2 using the ITC
data analysis module in ORIGIN version 2.9 provided by
Microcal.
Analytical Ultracentrifugation. The mechanism by which
10, 12, and 13 suppress fibril formation by wild type, V30M,
and L55P TTR was determined by incubating the protein at
3.6 íM for 72 h under the conditions of the stagnant fibril
formation assay in the presence of 10.8 íM of the test
compounds. Any precipitate that formed under these condi-
tions were removed by centrifugation at 14 000 rpm. The
quaternary structure of the protein that remained in the
supernatant was then analyzed using a Beckman XL-I ana-
lytical ultracentrifuge. The acquisition and analysis of data
was performed as described previously.11,29,59
Crystallization and X-ray Data Collection. Crystalsof-
recombinant TTR were obtained from protein solutions at 5
mg/mL (in 100 mM KCl, 100 mM phosphate, pH 7.4, 1 M
ammonium sulfate) equilibrated against 2 M ammonium
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sulfate in hanging drop experiments. The TTR-ligand com-
plexes were prepared from crystals soaked for 4 weeks with a
10-fold molar excess of the ligand to ensure full saturation of
both binding sites. For 10 and 11, a 1:1 acetone:water solution
was used as a soaking agent. A DIP2030 imaging plate system
(MAC Science, Yokohama, Japan) coupled to an RU200
rotating anode X-ray generator was used for data collection.
The crystals were placed in paratone oil as a cryo-protectant
and cooled to 120 K for our diffraction experiments. Crystals
of all TTR-ligand complexes are isomorphous with the apo
crystal form with unit cell dimensions a ) 43 Å, b ) 86 Å,
and c ) 65 Å. They belong to the space group P21212, and
contain half of the homotetramer in the asymmetric unit. Data
were reduced with DENZO and SCALEPACK.60
Structure Determination and Refinement. The protein
atomic coordinates for TTR from the Protein Data Bank
(accession number 1BMZ) were used as a starting model for
the refinement of native TTR and the TTR-ligand complexes
by molecular dynamics and energy minimization using the
program CNS.61 For the complexes of TTR with 10, 11, 12,
and 13, the resulting maps revealed binding of the ligand in
both binding pockets of the TTR tetramer. Using these maps,
the ligand could be unambiguously placed into the density and
was included in the crystallographic refinement. In all cases
the minimum energy conformation of the inhibitor calculated
by the program Insight II (Molecular Simulations Inc.) was
in good agreement with the initial annealed jFoj - jFcj maps
for the complex and was used as the initial model in the
crystallographic refinement. Because the 2-fold crystallo-
graphic symmetry axis is along the binding channel, a statisti-
cal disorder model had to be applied, giving rise to two ligand
binding modes in each of the two binding sites of tetrameric
TTR. After several cycles of simulated annealing and subse-
quent positional and temperature factor refinement, water
molecules were placed into difference Fourier maps. For the
four TTR-ligand complexes both symmetry related binding
conformations of the ligand were in good agreement with
unbiased annealed 2jFoj - jFcj omit maps, phased in the
absence of the inhibitor. Because of the lack of interpretable
electron densities in the final map, the nine N-terminal and
three C-terminal residues were not included in the final model.
A summary of the crystallographic analysis is presented in
Table 4.
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